Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
Our new study investigates biotechnology in pharma - biological drugs (biopharmaceuticals, biologics). It lets you assess potential sales trends at world market, submarket, product and regional level to 2022.
How will 20 leading biologics - including Avastin, Enbrel, Humira and Herceptin - perform from 2012? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of submarkets to 2022, finding potential revenues:
• Monoclonal antibodies (MAbs) and fusion proteins
• G-CSF agents
• Recombinant coagulation proteins
• Other therapeutic proteins
Find coverage of biopharmaceutical R&D pipelines too, assessing trends and outlooks.
What does the future hold? Despite economic pressures, the biopharma industry has great potential from 2012. Our report shows you how the importance of biological drugs will increase from 2012 to 2022, with expanding revenues and shares of pharma sales.
There are many promising developments in biopharma, including antibody-drug conjugates and bispecific monoclonal antibodies. R&D pipelines for biologics are strong.
What about leading companies? Our work discusses Roche, Amgen, Novo Nordisk, Abbott and many other pharmaceutical companies, evaluating prospects of the industry and market.
How will biosimilars (follow-on protein products) affect the market? Many commercial opportunities remain, with high revenues from original branded drugs and biosimilars predicted to 2022. Our report shows and explains.
You can investigate the future of biopharmaceuticals now, discovering sales potential.
Our study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers in the work.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you get qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 212 tables and charts and three research interviews.
Eight ways World Biological Drugs Market 2012-2022 helps you
In particular, this study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 20 leading products
• See market forecasting to 2022 for US, Japan, EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, receiving detailed interviews.
There, you find an original mix of quantitative and qualitative analyses with independent predictions. Receive information that only our report contains.
Through our analytical methods we keep you informed about commercial trends and prospects, helping you to stay ahead.
Gain business research and analysis now for the biopharma market
Our study is for everybody needing industry and market analyses for biological drugs. You find data, trends and answers there. Please order that report now.
American Society of Clinical Oncology
Biotechnology Regulatory Authority of India (BRAI)
Centocor Ortho Biotech
Chengdu Hoist Hitech
Dr. Reddy's Laboratories
European League Against Rheumatism
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (US FDA)
GKV Spitzenverband (Germany)
Hoechst Marion Roussel
Human Genome Sciences
International Nephrology Network
Johnson & Johnson
Kyowa Hakko Kirin
LG Life Sciences
Merchant & Gould P.C.
Merck & Co.
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Institute for Biological Standards and Control (NIBSC, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Pharmaceutical Research and Manufacturers of America (PhRMA)
RBC Capital Markets
Reliance Life Sciences
State Food and Drug Administration (China)
Swedish Orphan Biovitrum (Sobi)
Teva Pharmaceutical Industries
The National Hemophilia Foundation (US)
University Hospital of Tubingen
University of Leiden
University of Tokyo
Walter and Eliza Hall Institute